Septerna Inc
NASDAQ:SEPN

Watchlist Manager
Septerna Inc Logo
Septerna Inc
NASDAQ:SEPN
Watchlist
Price: 24.045 USD -5.52% Market Closed
Market Cap: $1.1B

Net Margin

-266.8%
Current
Improving
by 5 379.3%
vs 3-y average of -5 646%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-266.8%
=
Net Income
$-58.8m
/
Revenue
$22m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-266.8%
=
Net Income
$-58.8m
/
Revenue
$22m

Peer Comparison

Country Company Market Cap Net
Margin
US
Septerna Inc
NASDAQ:SEPN
1.1B USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
954.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
546.2B USD
Loading...
CH
Roche Holding AG
SIX:ROG
268.4B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
265.4B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
147.6B USD
Loading...
FR
Sanofi SA
PAR:SAN
94.4B EUR
Loading...

Market Distribution

Lower than 90% of companies in the United States of America
Percentile
10th
Based on 15 072 companies
10th percentile
-266.8%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Septerna Inc
Glance View

Market Cap
1.1B USD
Industry
Pharmaceuticals

Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. The company is headquartered in South San Francisco, California and currently employs 73 full-time employees. The company went IPO on 2024-10-25. The firm is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. The company is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. The company is focused in major therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.

SEPN Intrinsic Value
6.54 USD
Overvaluation 73%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-266.8%
=
Net Income
$-58.8m
/
Revenue
$22m
What is Septerna Inc's current Net Margin?

The current Net Margin for Septerna Inc is -266.8%, which is above its 3-year median of -5 646%.

How has Net Margin changed over time?

Over the last 1 years, Septerna Inc’s Net Margin has increased from -2 023.3% to -266.8%. During this period, it reached a low of -12 053% on Jun 30, 2025 and a high of -266.8% on Sep 30, 2025.

Back to Top